04.12.18

EyePoint Pharmaceuticals Strengthens Global IP With Notices of Allowance for Two U.S. Patents Related to Dexycu

Source: EyePoint Pharmaceuticals

EyePoint Pharmaceuticals announced that the U.S. Patent and Trademark Office (USPTO) has issued Notices of Allowance for two patents covering Dexycu, the company’s FDA-approved long-acting intraocular product for the treatment of postoperative inflammation.

The first patent (U.S. patent application number 14/124,631) includes claims relating to a method of treating inflammation of an eye following cataract surgery by delivering extremely small (4-6µL) amounts of dexamethasone in triethyl acetyl citrate. Once issued, this patent will expire in 2034. The second patent (U.S. patent application number 14/113,803) includes claims relating to loading and delivering a small dose volume from an injection syringe. Once issued, this patent will expire in 2032.

“These are significant milestones and represent the first patent allowances for Dexycu following the recently completed acquisition of Icon Bioscience,” Nancy Lurker, President and CEO, said in a company news release. “Today’s allowances strengthen our Dexycu IP portfolio related to the product’s delivery mechanism and enhances its value by extending its exclusivity out to 2034 and 2032, respectively.”

Dexycu is the first long-acting intraocular product approved by the FDA for the treatment of postoperative inflammation. Cataract surgery is the most frequent surgical procedure in the U.S., with approximately four million performed annually. Dexycu delivers a biodegradable extended-release formulation of dexamethasone into the posterior chamber of the eye via a single injection at the end of surgery, eliminating the burden of self-administering medicated eye drops several times a day for several weeks on a titrated schedule, in a primarily elderly patient population.

Related Content